Page last updated: 2024-11-02

pioglitazone and Focal Segmental Glomerulosclerosis

pioglitazone has been researched along with Focal Segmental Glomerulosclerosis in 5 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS."8.31Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023)
"While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS."4.31Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Hunley, TE1
Hidalgo, G1
Ng, KH1
Shirai, Y1
Miura, K1
Beng, HM1
Wu, Q1
Hattori, M1
Smoyer, WE1
Sharma, A1
Bourey, RE1
Edwards, JC1
Brink, DS1
Albert, SG1
Matsushita, K1
Yang, HC1
Mysore, MM1
Zhong, J1
Shyr, Y1
Ma, LJ1
Fogo, AB1
Toblli, JE1
Ferrini, MG1
Cao, G1
Vernet, D1
Angerosa, M1
Gonzalez-Cadavid, NF1
Zhou, TB1
Ou, C1
Luo, CP1
Xu, HL1

Other Studies

5 other studies available for pioglitazone and Focal Segmental Glomerulosclerosis

ArticleYear
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2023, Volume: 38, Issue:4

    Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S

2023
Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy.
    Diabetes research and clinical practice, 2021, Volume: 172

    Topics: Adult; Female; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Kidney Diseases; Li

2021
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
    Laboratory investigation; a journal of technical methods and pathology, 2016, Volume: 96, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Blood Pressure; Creatinine; Diseas

2016
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:8

    Topics: Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glomerulosclerosis, Focal

2009
Protective effects of PPARγ agonist in glomerulosclerosis rats induced by adriamycin.
    Renal failure, 2012, Volume: 34, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Glomerulosclerosis, Focal Segmental; Hypoglycemic

2012